TY - JOUR
T1 - Differential diagnosis of neuromyelitis optica spectrum disorders
AU - Kim, Sung Min
AU - Kim, Seong Joon
AU - Lee, Haeng Jin
AU - Kuroda, Hiroshi
AU - Palace, Jacqueline
AU - Fujihara, Kazuo
N1 - Publisher Copyright:
© SAGE Publications Ltd unless otherwise noted. Manuscript content on this site is licensed under Creative Commons Licenses.
PY - 2017/7/1
Y1 - 2017/7/1
N2 - Neuromyelitis optica spectrum disorder (NMOSD) is an inflammatory disorder of the central nervous system (CNS) mostly manifesting as optic neuritis and/or myelitis, which are frequently recurrent/bilateral or longitudinally extensive, respectively. As the autoantibody to aquaporin-4 (AQP4-Ab) can mediate the pathogenesis of NMOSD, testing for the AQP4-Ab in serum of patients can play a crucial role in diagnosing NMOSD. Nevertheless, the differential diagnosis of NMOSD in clinical practice is often challenging despite the phenotypical and serological characteristics of the disease because: (1) diverse diseases with autoimmune, vascular, infectious, or neoplastic etiologies can mimic these phenotypes of NMOSD; (2) patients with NMOSD may only have limited clinical manifestations, especially in their early disease stages; (3) test results for AQP4-Ab can be affected by several factors such as assay methods, serologic status, disease stages, or types of treatment; (4) some patients with NMOSD do not have AQP4-Ab; and (5) test results for the AQP4-Ab may not be readily available for the acute management of patients. Despite some similarity in their phenotypes, these NMOSD and NMOSD-mimics are distinct from each other in their pathogenesis, prognosis, and most importantly treatment. Understanding the detailed clinical, serological, radiological, and prognostic differences of these diseases will improve the proper management as well as diagnosis of patients.
AB - Neuromyelitis optica spectrum disorder (NMOSD) is an inflammatory disorder of the central nervous system (CNS) mostly manifesting as optic neuritis and/or myelitis, which are frequently recurrent/bilateral or longitudinally extensive, respectively. As the autoantibody to aquaporin-4 (AQP4-Ab) can mediate the pathogenesis of NMOSD, testing for the AQP4-Ab in serum of patients can play a crucial role in diagnosing NMOSD. Nevertheless, the differential diagnosis of NMOSD in clinical practice is often challenging despite the phenotypical and serological characteristics of the disease because: (1) diverse diseases with autoimmune, vascular, infectious, or neoplastic etiologies can mimic these phenotypes of NMOSD; (2) patients with NMOSD may only have limited clinical manifestations, especially in their early disease stages; (3) test results for AQP4-Ab can be affected by several factors such as assay methods, serologic status, disease stages, or types of treatment; (4) some patients with NMOSD do not have AQP4-Ab; and (5) test results for the AQP4-Ab may not be readily available for the acute management of patients. Despite some similarity in their phenotypes, these NMOSD and NMOSD-mimics are distinct from each other in their pathogenesis, prognosis, and most importantly treatment. Understanding the detailed clinical, serological, radiological, and prognostic differences of these diseases will improve the proper management as well as diagnosis of patients.
KW - Devic's disease
KW - aquaporin-4 antibody
KW - differential diagnosis
KW - longitudinally extensive transverse myelitis
KW - multiple sclerosis
KW - myelin oligodendrocyte glycoprotein antibody
KW - neuromyelitis optica spectrum disorders
KW - optic neuritis
UR - http://www.scopus.com/inward/record.url?scp=85020879129&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85020879129&partnerID=8YFLogxK
U2 - 10.1177/1756285617709723
DO - 10.1177/1756285617709723
M3 - Review article
AN - SCOPUS:85020879129
SN - 1756-2856
VL - 10
SP - 265
EP - 289
JO - Therapeutic Advances in Neurological Disorders
JF - Therapeutic Advances in Neurological Disorders
IS - 7
ER -